JP2018513150A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513150A5 JP2018513150A5 JP2017553109A JP2017553109A JP2018513150A5 JP 2018513150 A5 JP2018513150 A5 JP 2018513150A5 JP 2017553109 A JP2017553109 A JP 2017553109A JP 2017553109 A JP2017553109 A JP 2017553109A JP 2018513150 A5 JP2018513150 A5 JP 2018513150A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- enantiomer
- solvate
- diastereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 239000012453 solvate Substances 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000004067 bulking agent Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000007910 chewable tablet Substances 0.000 claims 1
- 229940068682 chewable tablet Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000007919 dispersible tablet Substances 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000008393 encapsulating agent Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 229940100688 oral solution Drugs 0.000 claims 1
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 0 C*c1cc2nccc(OC3CICCC(*)C3)c2cc1C(N)=O Chemical compound C*c1cc2nccc(OC3CICCC(*)C3)c2cc1C(N)=O 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019203698A JP6928774B2 (ja) | 2015-04-07 | 2019-11-11 | チロシンキナーゼ阻害剤およびそれを含む医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510161674 | 2015-04-07 | ||
| CN201510161674.4 | 2015-04-07 | ||
| PCT/CN2016/078703 WO2016161952A1 (zh) | 2015-04-07 | 2016-04-07 | 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019203698A Division JP6928774B2 (ja) | 2015-04-07 | 2019-11-11 | チロシンキナーゼ阻害剤およびそれを含む医薬組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018513150A JP2018513150A (ja) | 2018-05-24 |
| JP2018513150A5 true JP2018513150A5 (OSRAM) | 2018-08-02 |
| JP6617155B2 JP6617155B2 (ja) | 2019-12-11 |
| JP6617155B6 JP6617155B6 (ja) | 2020-01-22 |
Family
ID=57072288
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553109A Active JP6617155B6 (ja) | 2015-04-07 | 2016-04-07 | チロシンキナーゼ阻害剤およびそれを含む医薬組成物 |
| JP2019203698A Active JP6928774B2 (ja) | 2015-04-07 | 2019-11-11 | チロシンキナーゼ阻害剤およびそれを含む医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019203698A Active JP6928774B2 (ja) | 2015-04-07 | 2019-11-11 | チロシンキナーゼ阻害剤およびそれを含む医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10654808B2 (OSRAM) |
| EP (1) | EP3293177B1 (OSRAM) |
| JP (2) | JP6617155B6 (OSRAM) |
| CN (3) | CN107683279B (OSRAM) |
| WO (1) | WO2016161952A1 (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016378154B2 (en) * | 2015-12-25 | 2020-08-13 | Otsuka Pharmaceutical Factory, Inc. | Phenylimidazole compound |
| CN110023288B (zh) * | 2016-09-30 | 2022-10-28 | 广东众生睿创生物科技有限公司 | 酪氨酸激酶抑制剂的晶型、盐型以及制备方法 |
| CN110049969A (zh) * | 2017-02-07 | 2019-07-23 | 恩瑞生物医药科技（上海）有限公司 | 喹啉类化合物、其制备方法及其医药用途 |
| CN107115344B (zh) * | 2017-03-23 | 2019-06-14 | 广东众生睿创生物科技有限公司 | 酪氨酸激酶抑制剂在制备用于预防和/或治疗纤维化疾病的药物中的用途 |
| KR102327054B1 (ko) * | 2017-08-29 | 2021-11-17 | 기초과학연구원 | 퀴놀린 유도체 및 alk와 변이된 alk의 저해제로서의 용도 |
| CR20200140A (es) * | 2017-08-31 | 2020-05-15 | Abbvie Inc | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos |
| WO2019062637A1 (zh) * | 2017-09-28 | 2019-04-04 | 南京明德新药研发股份有限公司 | 喹啉衍生物及其作为酪氨酸激酶抑制剂的应用 |
| CN108623521B (zh) * | 2018-03-22 | 2020-09-04 | 盐城师范学院 | 一种乐伐替尼的制备方法 |
| CN110483482A (zh) * | 2018-05-15 | 2019-11-22 | 北京诺诚健华医药科技有限公司 | 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用 |
| CN110590839B (zh) * | 2018-06-13 | 2022-04-05 | 四川海思科制药有限公司 | 一种乐伐替尼衍生物及制备方法和用途 |
| CN110862397A (zh) * | 2018-08-27 | 2020-03-06 | 北京赛特明强医药科技有限公司 | 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用 |
| US12415816B2 (en) | 2018-11-07 | 2025-09-16 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| CN109485620A (zh) * | 2018-12-26 | 2019-03-19 | 安徽工大化工科技有限公司 | 一种2-甲氧基-6-甲氧基苯并噻唑的制备方法 |
| CA3128044A1 (en) * | 2019-02-01 | 2020-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enpp1 inhibitors and methods of modulating immune response |
| KR20210151818A (ko) * | 2019-04-12 | 2021-12-14 | 내셔날 헬스 리서치 인스티튜트 | 치료 용도를 위한 키나제 억제제로서의 헤테로사이클릭 화합물 |
| CN111892536B (zh) * | 2019-05-05 | 2022-06-28 | 北京福元医药股份有限公司 | 取代的喹啉甲酰胺类化合物及其用途 |
| CA3141424C (en) * | 2019-06-14 | 2023-11-07 | Zhengxia CHEN | Fused ring compound as fgfr and vegfr dual inhibitor |
| PE20221034A1 (es) * | 2019-08-08 | 2022-06-17 | B C I Pharma | Derivados de quinolina como inhibidores de proteina quinasa |
| CN113321654B (zh) * | 2020-02-28 | 2022-05-03 | 上海济煜医药科技有限公司 | 作为激酶抑制剂的稠合吡啶酮类化合物 |
| EP4146639A1 (en) | 2020-05-06 | 2023-03-15 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| TW202241889A (zh) | 2020-12-23 | 2022-11-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| CN113582924A (zh) * | 2021-09-09 | 2021-11-02 | 四川国康药业有限公司 | 一种多靶点酪氨酸激酶抑制剂及其制备方法和用途 |
| WO2023086320A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of jak2 |
| JP7782035B2 (ja) | 2021-11-09 | 2025-12-08 | エイジャックス セラピューティクス， インコーポレイテッド | Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール |
| CN114213404B (zh) * | 2021-12-27 | 2024-08-06 | 武汉九州钰民医药科技有限公司 | Vegfr抑制剂替沃扎尼的合成工艺 |
| CN118843617A (zh) * | 2022-03-29 | 2024-10-25 | 广东众生睿创生物科技有限公司 | 一种喹啉衍生物的晶型及其制备方法 |
| CN115215799B (zh) * | 2022-08-12 | 2024-05-31 | 上海爱博医药科技有限公司 | 脲类多靶点酪氨酸激酶抑制剂及其多种医药应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE300521T1 (de) * | 1996-09-25 | 2005-08-15 | Astrazeneca Ab | Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern |
| GB9904103D0 (en) * | 1999-02-24 | 1999-04-14 | Zeneca Ltd | Quinoline derivatives |
| MXPA03000252A (es) * | 2000-08-09 | 2003-06-06 | Astrazeneca Ab | Derivados de quinolina que tienen actividad de inhibicion de fcev. |
| HU230302B1 (hu) * | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
| MXPA06002296A (es) * | 2003-08-29 | 2006-05-22 | Pfizer | Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos. |
| GEP20084572B (en) | 2003-12-23 | 2008-12-25 | Pfizer | Novel quinoline derivatives |
| EP1711495A2 (en) * | 2004-01-23 | 2006-10-18 | Amgen Inc. | Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| CN101005843A (zh) | 2004-06-28 | 2007-07-25 | 布里斯托尔-迈尔斯·斯奎布公司 | 吡咯并三嗪激酶抑制剂 |
| WO2006125597A1 (en) * | 2005-05-24 | 2006-11-30 | Unilever N.V. | Toothbrush |
| WO2007061127A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
| RS56600B1 (sr) * | 2006-04-19 | 2018-02-28 | Novartis Ag | 6-o-supstituisana jedinjenja benzoksazola i benzotiazola i postupci inhibicije csf-1r signalinga |
| PT2287155E (pt) * | 2008-04-10 | 2013-07-26 | Taiho Pharmaceutical Co Ltd | Composto de aciltioureia ou um seu sal, e sua utilização |
| MX345552B (es) * | 2010-03-24 | 2017-02-02 | Amitech Therapeutic Solutions Inc | Compuestos heterocíclicos útiles para inhibición de cinasa. |
| MX2012014776A (es) * | 2010-06-25 | 2013-01-29 | Eisai R&D Man Co Ltd | Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados. |
| EP2680886B1 (en) * | 2011-02-28 | 2016-08-10 | Calitor Sciences, LLC | Substituted quinoline compounds |
| CN102816175B (zh) * | 2011-06-09 | 2015-12-16 | 上海汇伦生命科技有限公司 | 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途 |
| DK2780338T3 (en) * | 2011-11-14 | 2016-12-19 | Ignyta Inc | Uracil AS AXL- AND C-MET kinase inhibitors |
| WO2013180949A1 (en) * | 2012-05-27 | 2013-12-05 | Ning Xi | Substituted quinoline compounds and methods of use |
| US9334239B2 (en) * | 2012-12-21 | 2016-05-10 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| EA201691850A1 (ru) * | 2014-03-17 | 2016-12-30 | Экселиксис, Инк. | Дозирование составов, содержащих кабозантиниб |
-
2016
- 2016-04-07 US US15/562,825 patent/US10654808B2/en active Active
- 2016-04-07 EP EP16776127.9A patent/EP3293177B1/en active Active
- 2016-04-07 CN CN201680019729.0A patent/CN107683279B/zh active Active
- 2016-04-07 CN CN202011033493.0A patent/CN112028825B/zh active Active
- 2016-04-07 CN CN201610211659.0A patent/CN106046007B/zh active Active
- 2016-04-07 JP JP2017553109A patent/JP6617155B6/ja active Active
- 2016-04-07 WO PCT/CN2016/078703 patent/WO2016161952A1/zh not_active Ceased
-
2019
- 2019-11-11 JP JP2019203698A patent/JP6928774B2/ja active Active